Group 1: Market Performance - The Hong Kong pharmaceutical and biotechnology sector has shown strong performance, with the Hang Seng Healthcare Index ETF (159557) rising 1.9% as of May 21, aiming for a fourth consecutive increase, with a premium rate of 0.23% [1] - Over the three trading days from May 16 to May 20, the Hang Seng Healthcare Index ETF (159557) accumulated a total increase of approximately 6.4% [1] - Notable individual stock performances include Ascentage Pharma-B rising over 10%, and other companies like CanSino Biologics, Innovent Biologics, and 3SBio increasing by over 6% [1] Group 2: Company Developments - 3SBio announced a significant agreement with Pfizer on May 20, granting exclusive rights for the global development, production, and commercialization of its PD-1/VEGF bispecific antibody SSGJ-707, excluding mainland China [2] - The agreement includes an upfront payment of $1.25 billion and potential milestone payments totaling up to $4.8 billion, leading to a total potential transaction value of $6.05 billion, which exceeds 43 billion RMB at current exchange rates [2] - This transaction sets a new record for the highest upfront payment for a domestic innovative drug license-out deal [2] Group 3: Industry Outlook - The innovative drug sector is expected to maintain its growth trajectory, driven by "innovation + internationalization," supported by policy backing and enhanced global competitiveness [3] - There is an anticipated recovery in demand for domestic healthcare services by 2025, with potential improvements in the medical device sector as well [3] - AI in healthcare is highlighted as a significant technological trend that could bring new changes to the pharmaceutical industry [3] - Long-term prospects suggest that companies with strong innovation capabilities and rich product pipelines will benefit from ongoing procurement initiatives in pharmaceuticals and consumables [3]
港股医药板块延续涨势，恒生医疗指数ETF（159557）涨近2%冲击四连涨，机构：“创新+国际化”始终是医药板块核心方向